Home News Article

Voluntary Recall on Ranitidine Hydrochloride Capsules

October 17, 2019

On September 23, 2019, Sandoz Inc. issued a voluntary recall of Ranitidine Hydrochloride Capsules 150mg and 300mg due to an elevated amount of unexpected impurity, N-Nitrosodimethylamine (NDMA) in the product.

Patients are asked to continue taking their medication and speak to their provider about alternate healthcare treatment options. Pharmacies will be asked to immediately stop dispensing Sandoz Ranitidine Hydrochloride Capsules

Visit the FDA website for more information on the recalled products including product names, catalog numbers, lot numbers, and expiration dates. For other questions, email provider.relationswest@premera.com.